Headache Medicine

Migraine treatment has been revolutionized by the CGRP pathway, with four anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) for prevention and the gepant class (ubrogepant, rimegepant, atogepant, zavegepant nasal spray) bridging acute and preventive use. GCNN 2027 will review long-term real-world effectiveness and safety, switching algorithms, and emerging data on gepants in menstrual and vestibular migraine. The track will also cover ditans (lasmiditan), remote electrical neuromodulation and non-invasive vagal stimulation, cluster headache (galcanezumab, occipital nerve stimulation), and the persistent challenge of medication overuse headache.